{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,2,21]],"date-time":"2026-02-21T11:39:36Z","timestamp":1771673976490,"version":"3.50.1"},"reference-count":99,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2021,1,29]],"date-time":"2021-01-29T00:00:00Z","timestamp":1611878400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2021,1,29]],"date-time":"2021-01-29T00:00:00Z","timestamp":1611878400000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Ital J Pediatr"],"abstract":"<jats:title>Abstract<\/jats:title><jats:sec>\n                <jats:title>Purpose of review<\/jats:title>\n                <jats:p>Despite its recognized efficacy and tolerability profile, during the last decade a rise of adverse events following ibuprofen administration in children has been reported, including a possible role in worsening the clinical course of infections. Our aim was to critically evaluate the safety of ibuprofen during the course of pediatric infectious disease in order to promote its appropriate use in children.<\/jats:p>\n              <\/jats:sec><jats:sec>\n                <jats:title>Recent findings<\/jats:title>\n                <jats:p>Ibuprofen is associated with severe necrotizing soft tissue infections (NSTI) during chickenpox course. Pre-hospital use of ibuprofen seems to increase the risk of complicated pneumonia in children. Conflicting data have been published in septic children, while ibuprofen in the setting of Cystic Fibrosis (CF) exacerbations is safe and efficacious. No data is yet available for ibuprofen use during COVID-19 course.<\/jats:p>\n              <\/jats:sec><jats:sec>\n                <jats:title>Summary<\/jats:title>\n                <jats:p>Ibuprofen should not be recommended for chickenpox management. Due to possible higher risks of complicated pneumonia, we suggest caution on its use in children with respiratory symptoms. While it remains unclear whether ibuprofen may have harmful effects during systemic bacterial infection, its administration is recommended in CF course. Despite the lack of data, it is seems cautious to prefer the use of paracetamol during COVID-19 acute respiratory distress syndrome in children.<\/jats:p>\n              <\/jats:sec>","DOI":"10.1186\/s13052-021-00974-0","type":"journal-article","created":{"date-parts":[[2021,1,29]],"date-time":"2021-01-29T11:18:12Z","timestamp":1611919092000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":27,"title":["Serious infectious events and ibuprofen administration in pediatrics: a narrative review in the era of COVID-19 pandemic"],"prefix":"10.1186","volume":"47","author":[{"given":"Lucia","family":"Quaglietta","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Massimo","family":"Martinelli","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-0586-1339","authenticated-orcid":false,"given":"Annamaria","family":"Staiano","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2021,1,29]]},"reference":[{"key":"974_CR1","volume-title":"Fever in under 5s: assessment and initial management","author":"NICE Guideline Updates Team (UK)","year":"2019","unstructured":"NICE Guideline Updates Team (UK). Fever in under 5s: assessment and initial management. London: National Institute for Health and Care Excellence (UK); 2019."},{"key":"974_CR2","doi-asserted-by":"publisher","first-page":"177","DOI":"10.1016\/j.jpeds.2016.09.043","volume":"180","author":"E Chiappini","year":"2017","unstructured":"Chiappini E, Venturini E, Remaschi G, et al. Italian Pediatric Society Panel for the Management of Fever in Children. 2016 Update of the Italian Pediatric Society Guidelines for Management of Fever in Children. J Pediatr. 2017;180:177\u2013183.e1.","journal-title":"J Pediatr"},{"key":"974_CR3","first-page":"580","volume":"c127","author":"JE Sullivan","year":"2011","unstructured":"Section on Clinical Pharmacology and Therapeutics; Committee on Drugs, Sullivan JE, Farrar HC. Fever and antipyretic use in children. Pediatrics. 2011;c127:580\u20137.","journal-title":"Pediatrics"},{"key":"974_CR4","doi-asserted-by":"publisher","first-page":"2207","DOI":"10.1185\/03007990903116255","volume":"25","author":"ER Southey","year":"2009","unstructured":"Southey ER, Soares-Weiser K, Kleijnen J. Systematic review and meta-analysis of the clinical safety and tolerability of ibuprofen compared with paracetamol in paediatric pain and fever. Curr Med Res Opin. 2009;25:2207\u201322.","journal-title":"Curr Med Res Opin"},{"key":"974_CR5","doi-asserted-by":"publisher","first-page":"489","DOI":"10.1345\/aph.1M332","volume":"44","author":"CA Pierce","year":"2010","unstructured":"Pierce CA, Voss B. Efficacy and safety of ibuprofen and acetaminophen in children and adults: a meta-analysis and qualitative review. Ann Pharmacother. 2010;44:489\u2013506.","journal-title":"Ann Pharmacother"},{"key":"974_CR6","doi-asserted-by":"publisher","first-page":"521","DOI":"10.1001\/archpedi.158.6.521","volume":"158","author":"DA Perrott","year":"2004","unstructured":"Perrott DA, Piira T, Goodenough B, Champion GD. Efficacy and safety of acetaminophen vs ibuprofen for treating children\u2019s pain or fever: a meta-analysis. Arch Pediatr Adolesc Med. 2004;158:521\u20136.","journal-title":"Arch Pediatr Adolesc Med"},{"key":"974_CR7","doi-asserted-by":"publisher","first-page":"817","DOI":"10.2165\/00128072-200103110-00004","volume":"3","author":"C Litalien","year":"2001","unstructured":"Litalien C, Jacqz-Aigrain E. Risks and benefits of nonsteroidal anti-inflammatory drugs in children: a comparison with paracetamol. Paediatr Drugs. 2001;3:817\u201358.","journal-title":"Paediatr Drugs."},{"key":"974_CR8","first-page":"9","volume":"135","author":"E Autret-Leca","year":"2003","unstructured":"Autret-Leca E. A general overview of the use of ibuprofen in paediatrics. Int J Clin Pract Suppl. 2003;135:9\u201312.","journal-title":"Int J Clin Pract Suppl"},{"key":"974_CR9","doi-asserted-by":"publisher","first-page":"929","DOI":"10.1001\/jama.1995.03520360043037","volume":"273","author":"SM Lesko","year":"1995","unstructured":"Lesko SM, Mitchell AA. An assessment of the safety of pediatric ibuprofen. A practitioner-based randomized clinical trial. JAMA. 1995;273:929\u201333.","journal-title":"JAMA."},{"key":"974_CR10","first-page":"654","volume":"10","author":"P Baiardi","year":"2010","unstructured":"Baiardi P, Barbieri I, Del Principe D, et al. Cautele sull\u2019uso dei FANS nei bambini. Le raccomandazioni del Working Group Pediatrico dell\u2019AIFA. Medico e Bambino. 2010;10:654\u20136.","journal-title":"Medico e Bambino"},{"key":"974_CR11","doi-asserted-by":"publisher","first-page":"1877","DOI":"10.3748\/wjg.v22.i5.1877","volume":"22","author":"S Cardile","year":"2016","unstructured":"Cardile S, Martinelli M, Barabino A, et al. Italian survey on non-steroidal anti-inflammatory drugs and gastrointestinal bleeding in children. World J Gastroenterol. 2016;22:1877\u201383.","journal-title":"World J Gastroenterol"},{"key":"974_CR12","doi-asserted-by":"publisher","first-page":"831","DOI":"10.1007\/s00228-010-0832-3","volume":"66","author":"L Grimaldi-Bensouda","year":"2010","unstructured":"Grimaldi-Bensouda L, Abenhaim L, Michaud L, et al. Clinical features and risk factors for upper gastrointestinal bleeding in children: a case-crossover study. Eur J Clin Pharmacol. 2010;66:831\u20137.","journal-title":"Eur J Clin Pharmacol"},{"key":"974_CR13","doi-asserted-by":"publisher","first-page":"218","DOI":"10.1136\/archdischild-2012-302100","volume":"98","author":"M Bianciotto","year":"2013","unstructured":"Bianciotto M, Chiappini E, Raffaldi I. Et al; Italian multicenter study Group for Drug and Vaccine Safety in children. Drug use and upper gastrointestinal complications in children: a case-control study. Arch Dis Child. 2013;98:218\u201321.","journal-title":"Arch Dis Child"},{"key":"974_CR14","doi-asserted-by":"publisher","first-page":"1873","DOI":"10.1007\/s00467-015-3105-7","volume":"30","author":"A Balestracci","year":"2015","unstructured":"Balestracci A, Ezquer M, Elmo ME, et al. Ibuprofen-associated acute kidney injury in dehydrated children with acute gastroenteritis. Pediatr Nephrol. 2015;30:1873\u20138.","journal-title":"Pediatr Nephrol"},{"key":"974_CR15","doi-asserted-by":"publisher","first-page":"61","DOI":"10.1007\/s12325-019-01144-9","volume":"37","author":"G Varrassi","year":"2020","unstructured":"Varrassi G, Pergolizzi JV, Dowling P, Paladini A. Ibuprofen safety at the Golden anniversary: are all NSAIDs the same? A Narrative Review. Adv Ther. 2020;37:61\u201382.","journal-title":"Adv Ther"},{"key":"974_CR16","doi-asserted-by":"publisher","first-page":"R43","DOI":"10.1186\/cc7766","volume":"13","author":"A Legras","year":"2009","unstructured":"Legras A, Giraudeau B, Jonville-Bera A-P, et al. A multicentre case-control study of non steroidal anti-inflammatory drugs as a risk factor for severe sepsis and septic shock. Crit Care. 2009;13:R43.","journal-title":"Crit Care"},{"key":"974_CR17","volume-title":"[Anti-inflammatoires non-steroidiens (AINS) et complications infectieuses graves-Point d\u2019Information]. Agence nationale de securite du medicament et des produits de sante","author":"ANSM","year":"2019","unstructured":"ANSM. [Anti-inflammatoires non-steroidiens (AINS) et complications infectieuses graves-Point d\u2019Information]. Agence nationale de securite du medicament et des produits de sante. 2019. https:\/\/ansm.sante.fr\/S-informer\/Points-d-information-Points-d-information\/Anti-inflammatoires-nonsteroidiens-AINS-et-complications-infectieuses-graves-Point-d-Information. Accessed 4 Jun 2019."},{"key":"974_CR18","volume-title":"France\u2019s ANSM warns about NSAIDs following safety review. Regulatory Affairs Profession- als. EU Regulatory Roundup Web site","author":"N Taylor","year":"2019","unstructured":"Taylor N. France\u2019s ANSM warns about NSAIDs following safety review. Regulatory Affairs Profession- als. EU Regulatory Roundup Web site. 2019. https:\/\/www.raps.org\/news-and-articles\/news-articles\/2019\/4\/eu-regulatory-roundup-frances-ansm-warns-about-n. Accessed 4 Jun 2019."},{"key":"974_CR19","unstructured":"https:\/\/www.ansm.sante.fr\/S-informer\/Points-d-information-Points-d-information\/Anti-inflammatoires-non-steroidiens-AINS-et-complications-infectieuses-graves-Point-d-Information-actualise-le-20-05-2020."},{"key":"974_CR20","unstructured":"https:\/\/www.ansm.sante.fr\/S-informer\/Communiques-Communiques-Points-presse\/Fievre-et-douleur-chez-l-enfant-atteint-de-varicelle-l-utilisation-d-anti-inflammatoires-non-steroidiens-n-est-pas-recommandee."},{"key":"974_CR21","first-page":"1163","volume":"17","author":"V Le","year":"2016","unstructured":"Le V, Kurnutala L, Schiano di Cola J, et al. Premedication with intravenous ibuprofen improves recovery characteristics and stress response in adults undergoing laparoscopic cholecystectomy: a randomized controlled trial. Pain Med. 2016;17:1163\u201373.","journal-title":"Pain Med"},{"key":"974_CR22","doi-asserted-by":"publisher","first-page":"473","DOI":"10.1189\/jlb.4A0214-093RR","volume":"96","author":"CH Canan","year":"2014","unstructured":"Canan CH, Gokhale NS, Carruthers B, et al. Characterization of lung inflammation and its impact on macrophage function in aging. J Leukoc Biol. 2014;96:473\u201380.","journal-title":"J Leukoc Biol"},{"key":"974_CR23","doi-asserted-by":"publisher","first-page":"783","DOI":"10.1542\/peds.103.4.783","volume":"103","author":"DM Zerr","year":"1999","unstructured":"Zerr DM, Alexander ER, Duchin JS, et al. A case-control study of necrotizing fasciitis during primary varicella. Pediatrics. 1999;103:783\u201390.","journal-title":"Pediatrics"},{"key":"974_CR24","doi-asserted-by":"publisher","first-page":"47","DOI":"10.1016\/j.jpeds.2016.05.025","volume":"175","author":"M Le Bourgeois","year":"2016","unstructured":"Le Bourgeois M, Ferroni A, Leruez-Ville M, et al. Nonsteroidal anti-inflammatory drug without antibiotics for acute viral infection increases the empyema risk in children: a matched case-control study. J Pediatr. 2016;175:47\u201353.","journal-title":"J Pediatr"},{"key":"974_CR25","doi-asserted-by":"publisher","first-page":"2666","DOI":"10.1017\/S0950268817001546","volume":"145","author":"K Bollaerts","year":"2017","unstructured":"Bollaerts K, Riera-Montes M, Heininger U, et al. A systematic review of varicella seroprevalence in European countries before universal childhood immunization: deriving incidence from seroprevalence data. Epidemiol Infect. 2017;145:2666\u201377.","journal-title":"Epidemiol Infect"},{"key":"974_CR26","doi-asserted-by":"publisher","first-page":"440","DOI":"10.1016\/S1047-2797(97)00040-9","volume":"7","author":"PW Choo","year":"1997","unstructured":"Choo PW, Donahue JG, Platt R. Ibuprofen and skin and soft tissue superinfections in children with varicella. Ann Epidemiol. 1997;7:440\u20135.","journal-title":"Ann Epidemiol"},{"key":"974_CR27","doi-asserted-by":"publisher","first-page":"1108","DOI":"10.1542\/peds.107.5.1108","volume":"107","author":"SM Lesko","year":"2001","unstructured":"Lesko SM, O\u2019Brien KL, Schwartz B, Vezina R, Mitchell AA. Invasive group a streptococcal infection and nonsteroidal antiinflammatory drug use among children with primary varicella. Pediatrics. 2001;107:1108\u201315.","journal-title":"Pediatrics."},{"key":"974_CR28","doi-asserted-by":"publisher","first-page":"203","DOI":"10.1111\/j.1365-2125.2007.02997.x","volume":"65","author":"Y Mikaeloff","year":"2008","unstructured":"Mikaeloff Y, Kezouh A, Suissa S. Nonsteroidal anti-inflammatory drug use and the risk of severe skin and soft tissue complications in patients with varicella or zoster disease. Br J Clin Pharmacol. 2008;65:203\u20139.","journal-title":"Br J Clin Pharmacol"},{"key":"974_CR29","doi-asserted-by":"publisher","first-page":"249","DOI":"10.1111\/j.1365-2230.2007.02652.x","volume":"33","author":"C Souyri","year":"2008","unstructured":"Souyri C, Olivier P, Grolleau S, Lapeyre-Mestre M. French network of Pharmacovigilance Centres. Severe necrotizing soft- tissue infections and nonsteroidal anti-inflammatory drugs. Clin Exp Dermatol. 2008;33:249\u201355.","journal-title":"Clin Exp Dermatol"},{"key":"974_CR30","doi-asserted-by":"publisher","first-page":"26","DOI":"10.2340\/00015555-0333","volume":"88","author":"F Dubos","year":"2008","unstructured":"Dubos F, Hue V, Grandbastien B, et al. Bacterial skin infections in children hospitalized with varicella: a possible negative impact of non-steroidal anti-inflammatory drugs? Acta Derm Venereol. 2008;88:26\u201330.","journal-title":"Acta Derm Venereol"},{"key":"974_CR31","doi-asserted-by":"publisher","first-page":"975","DOI":"10.1007\/s11096-015-0184-2","volume":"37","author":"L Durand","year":"2015","unstructured":"Durand L, Sachs P, Lemaitre C, et al. NSAIDs in paediatrics: caution with varicella! Int J Clin Pharm. 2015;37:975\u20137.","journal-title":"Int J Clin Pharm"},{"key":"974_CR32","doi-asserted-by":"publisher","first-page":"801","DOI":"10.1001\/jama.2016.0287","volume":"315","author":"M Singer","year":"2016","unstructured":"Singer M, Deutschman CS, Seymour CW, et al. The third international consensus definitions for sepsis and septic shock (sepsis-3). JAMA. 2016;315:801.","journal-title":"JAMA"},{"key":"974_CR33","doi-asserted-by":"publisher","first-page":"1786","DOI":"10.1136\/bmj.290.6484.1786","volume":"290","author":"CJ Brun-Buisson","year":"1985","unstructured":"Brun-Buisson CJ, Saada M, Trunet P, et al. Haemolytic streptococcal gangrene and non-steroidal anti- inflammatorydrugs. Br Med J (Clin Res Ed). 1985;290:1786.","journal-title":"Br Med J (Clin Res Ed)"},{"key":"974_CR34","doi-asserted-by":"publisher","first-page":"143","DOI":"10.1093\/infdis\/155.1.143","volume":"155","author":"A Rimailho","year":"1987","unstructured":"Rimailho A, Riou B, Richard C, Auzepy P. Fulminant necrotizing fasciitis and nonsteroidal anti-inflammatory drugs. J Infect Dis. 1987;155:143\u20136.","journal-title":"J Infect Dis"},{"key":"974_CR35","doi-asserted-by":"publisher","first-page":"1194","DOI":"10.1007\/s00134-002-1376-5","volume":"28","author":"W Schummer","year":"2002","unstructured":"Schummer W, Schummer C. Nonsteroidal anti-inflammatory drugs and streptococcal toxic shock syndrome. Intensive Care Med. 2002;28:1194.","journal-title":"Intensive Care Med"},{"key":"974_CR36","doi-asserted-by":"publisher","first-page":"1831. 3","DOI":"10.1007\/s001340101070","volume":"27","author":"RP Veenstra","year":"2001","unstructured":"Veenstra RP, Manson WE, Werf TS, et al. Fulminant necrotizing fasciitis and nonster-oidal anti-inflammatory drugs. Intensive Care Med. 2001;27:1831. 3.","journal-title":"Intensive Care Med"},{"key":"974_CR37","doi-asserted-by":"publisher","first-page":"369","DOI":"10.2165\/00002018-199717060-00003","volume":"17","author":"EP Holder","year":"1997","unstructured":"Holder EP, Moore PT, Browne BA. Nonsteroidal anti-inflammatory drugs and necrotising fasciitis. An update. Drug Saf. 1997;17:369\u201373.","journal-title":"Drug Saf"},{"key":"974_CR38","doi-asserted-by":"publisher","first-page":"225","DOI":"10.1097\/01.md.0000085060.63483.bb","volume":"82","author":"DM Aronoff","year":"2003","unstructured":"Aronoff DM, Bloch KC. Assessing the relationship between the use of nonsteroidal antiinflammatory drugs and necrotizing fascitis caused by group A streptococcus. Medicine. 2003;82:225\u201335.","journal-title":"Medicine"},{"key":"974_CR39","doi-asserted-by":"publisher","first-page":"642","DOI":"10.1542\/peds.2004-2300","volume":"115","author":"BE Gonzalez","year":"2005","unstructured":"Gonzalez BE, Martinez-Aguilar G, Hulten KG, et al. Severe staphylococcal sepsis in adolescents in the era of community-acquired methicillin-resistant S aureus. Pediatrics. 2005;115:642\u20138.","journal-title":"Pediatrics"},{"key":"974_CR40","doi-asserted-by":"publisher","first-page":"977","DOI":"10.1093\/clinids\/21.4.977","volume":"21","author":"DL Stevens","year":"1995","unstructured":"Stevens DL. Could nonsteroidal antiinflammatory drugs (NSAIDs) enhance the progression of bacterial infections to toxic shock syndrome? Clin Infect Dis. 1995;21:977\u201380.","journal-title":"Clin Infect Dis"},{"key":"974_CR41","doi-asserted-by":"publisher","first-page":"543","DOI":"10.1016\/S1047-2797(03)00071-1","volume":"13","author":"ZD Mulla","year":"2003","unstructured":"Mulla ZD. Nonsteroidal anti-inflammatory drugs and hypotension among patients hospitalized for invasive group a streptococcal disease. Ann Epidemiol. 2003;13:543\u20134.","journal-title":"Ann Epidemiol"},{"key":"974_CR42","doi-asserted-by":"publisher","first-page":"550","DOI":"10.1177\/0009922807299940","volume":"46","author":"A Burnett","year":"2007","unstructured":"Burnett A, Domachowske JB. Therapeutic Considerations for Children With Invasive Group A Streptococcal Infections: A Case Series Report and Review of the Literature. Clin Pediatr (Phila). 2007;46:550\u20135.","journal-title":"Clin Pediatr (Phila)"},{"key":"974_CR43","doi-asserted-by":"publisher","first-page":"174","DOI":"10.1046\/j.1469-0691.2002.00396.x","volume":"8","author":"MR Barnham","year":"2002","unstructured":"Barnham MR, Weightman NC, Anderson AW, Tanna A. Streptococcal toxic shock syndrome: a description of 14 cases from North Yorkshire, UK. Clin Microbiol Infect. 2002;8:174\u201381.","journal-title":"Clin Microbiol Infect"},{"key":"974_CR44","doi-asserted-by":"publisher","first-page":"202","DOI":"10.3201\/eid1402.070888","volume":"14","author":"TL Lamagni","year":"2008","unstructured":"Lamagni TL, Neal S, Keshishian C, et al. Severe Streptococcus pyogenes infections, United Kingdom, 2003\u20132004. Emerg Infect Dis. 2008;14:202\u20139.","journal-title":"Emerg Infect Dis"},{"key":"974_CR45","doi-asserted-by":"publisher","first-page":"912","DOI":"10.1056\/NEJM199703273361303","volume":"336","author":"GR Bernard","year":"1997","unstructured":"Bernard GR, Wheeler AP, Russell JA, et al. The effects of ibuprofen on the physiology and survival of patients with sepsis: the ibuprofen in Sepsis study group. N Engl J Med. 1997;336:912\u20138.","journal-title":"N Engl J Med"},{"key":"974_CR46","doi-asserted-by":"publisher","first-page":"195","DOI":"10.1016\/j.earlhumdev.2011.07.021","volume":"88","author":"G Demirel","year":"2012","unstructured":"Demirel G, Celik IH, Canpolat FE, et al. The effects of ibuprofen on sepsis parameters in preterm neonates. Early Hum Dev. 2012;88:195\u20136.","journal-title":"Early Hum Dev"},{"key":"974_CR47","doi-asserted-by":"publisher","first-page":"9","DOI":"10.2165\/11532890-000000000-00000","volume":"30","author":"S Leroy","year":"2010","unstructured":"Leroy S, Marc E, Bavoux F, et al. Hospitalization for severe bacterial infections in children after exposure to NSAIDs: a prospective adverse drug reaction reporting study. Clin Drug Investig. 2010;30:9\u201385.","journal-title":"Clin Drug Investig"},{"key":"974_CR48","doi-asserted-by":"publisher","first-page":"434","DOI":"10.1086\/338460","volume":"34","author":"CL Byington","year":"2002","unstructured":"Byington CL, Spencer LY, Johnson TA, et al. An epidemiological investigation of a sustained high rate of pediatric parapneumonic empyema: risk factors and microbiological associations. Clin Infect Dis. 2002;34:434\u201340.","journal-title":"Clin Infect Dis"},{"key":"974_CR49","doi-asserted-by":"publisher","first-page":"861","DOI":"10.1111\/j.1651-2227.2010.01734.x","volume":"99","author":"P Fran\u00e7ois","year":"2010","unstructured":"Fran\u00e7ois P, Desrumaux A, Cans C, et al. Prevalence and risk factors of suppurative complications in children with pneumonia. Acta Paediatr. 2010;99:861\u20136.","journal-title":"Acta Paediatr"},{"key":"974_CR50","doi-asserted-by":"publisher","first-page":"721","DOI":"10.1002\/ppul.23041","volume":"50","author":"MA Elemraid","year":"2015","unstructured":"Elemraid MA, Thomas MF, Blain AP, et al. Risk factors for the development of pleural empyema in children. Pediatr Pulmonol. 2015;50:721\u20136.","journal-title":"Pediatr Pulmonol"},{"key":"974_CR51","doi-asserted-by":"publisher","first-page":"253","DOI":"10.1111\/crj.12524","volume":"12","author":"K Krenke","year":"2018","unstructured":"Krenke K, Krawiec M, Kraj G, et al. Risk factors for local complications in children with community-acquired pneumonia. Clin Respir J. 2018;12:253\u201361.","journal-title":"Clin Respir J"},{"key":"974_CR52","doi-asserted-by":"publisher","first-page":"140","DOI":"10.1007\/s12098-018-2769-y","volume":"86","author":"P Meganathan","year":"2019","unstructured":"Meganathan P, Awasthi S. Predicting Complicated Parapneumonic Effusion in Community Acquired Pneumonia: Hospital Based Case- Control Study. Indian J Pediatr. 2019;86:140\u20137.","journal-title":"Indian J Pediatr"},{"key":"974_CR53","doi-asserted-by":"publisher","first-page":"848","DOI":"10.1056\/NEJM199503303321303","volume":"332","author":"MW Konstan","year":"1995","unstructured":"Konstan MW, Byard PJ, Hoppel CL, Davis PB. Effect of high-dose ibuprofen in patients with cystic fibrosis. N Engl J Med. 1995;332:848\u201354.","journal-title":"N Engl J Med"},{"key":"974_CR54","first-page":"118","volume":"67","author":"DO Sordelli","year":"1985","unstructured":"Sordelli DO, Cerquetti MC, el-Tawil G, Ramwell PW, Hooke AM, Bellanti JA. Ibuprofen modifies the inflammatory response of the murine lung to Pseudomonas aeruginosa. Eur J Respir Dis. 1985;67:118\u201327.","journal-title":"Eur J Respir Dis"},{"key":"974_CR55","doi-asserted-by":"publisher","first-page":"381","DOI":"10.2165\/00128072-200204060-00005","volume":"4","author":"A Jaffe","year":"2002","unstructured":"Jaffe A, Balfour-Lynn IM. Treatment of severe small airways disease in children with cystic fibrosis: alternatives to corticosteroids. Paediatr Drugs. 2002;4:381\u20139.","journal-title":"Paediatr Drugs"},{"key":"974_CR56","doi-asserted-by":"publisher","first-page":"186","DOI":"10.1164\/ajrccm\/141.1.186","volume":"141","author":"MW Konstan","year":"1990","unstructured":"Konstan MW, Vargo KM, Davis PB. Ibuprofen attenuates the inflammatory response to Pseudomonas aeruginosa in a rat model of chronic pulmonary infection. Implications for antiinflammatory therapy in cystic fibrosis. Am Rev Respir Dis. 1990;141:186\u201319.","journal-title":"Am Rev Respir Dis"},{"key":"974_CR57","doi-asserted-by":"publisher","first-page":"249","DOI":"10.1016\/j.jpeds.2007.04.009","volume":"151","author":"LC Lands","year":"2007","unstructured":"Lands LC, Milner R, Cantin AM, Manson D, Corey M. High-dose ibuprofen in cystic fibrosis: Canadian safety and effectiveness trial. J Pediatr. 2007;151:249\u201354.","journal-title":"J Pediatr"},{"key":"974_CR58","doi-asserted-by":"crossref","unstructured":"Lands LC, Stanojevic S. Oral non-steroidal anti-inflammatory drug therapy for cystic fibrosis. Cochrane Database Syst Rev. 2007;(4):CD001505.","DOI":"10.1002\/14651858.CD001505.pub2"},{"key":"974_CR59","doi-asserted-by":"crossref","unstructured":"Lands LC, Stanojevic S. Oral non-steroidal anti-inflammatory drug therapy for lung disease in cystic fibrosis. Cochrane Database Syst Rev. 2013;(6):CD001505.","DOI":"10.1002\/14651858.CD001505.pub3"},{"key":"974_CR60","doi-asserted-by":"crossref","unstructured":"Lands LC, Stanojevic S. Oral non-steroidal anti-inflammatory drug therapy for lung disease in cystic fibrosis. Cochrane Database Syst Rev. 2016;4:CD001505.","DOI":"10.1002\/14651858.CD001505.pub4"},{"key":"974_CR61","doi-asserted-by":"crossref","unstructured":"Lands LC, Stanojevic S. Oral non-steroidal anti-inflammatory drug therapy for lung disease in cystic fibrosis. Cochrane Database Syst Rev. 2019;9(9):CD001505.","DOI":"10.1002\/14651858.CD001505.pub5"},{"key":"974_CR62","doi-asserted-by":"publisher","first-page":"3","DOI":"10.1128\/AAC.01574-17","volume":"62","author":"PN Shah","year":"2018","unstructured":"Shah PN, Marshall-Batty KR, Smolen A, et al. Antimicrobial activity of ibuprofen against cystic fibrosis-associated gram-negative pathogens. Antimicrob Agents Chemother. 2018;62:3.","journal-title":"Antimicrob Agents Chemother"},{"issue":"11","key":"974_CR63","doi-asserted-by":"publisher","first-page":"694","DOI":"10.21037\/atm-20-2793","volume":"8","author":"KK Sahu","year":"2020","unstructured":"Sahu KK, Mishra AK, Lal A. Trajectory of the COVID-19 pandemic: chasing a moving target. Ann Transl Med. 2020;8(11):694.","journal-title":"Ann Transl Med"},{"key":"974_CR64","volume-title":"Coronavirus disease (CO- VID-2019) situation reports","author":"World Health Organization","year":"2020","unstructured":"World Health Organization. Coronavirus disease (CO- VID-2019) situation reports. 2020. Accessed 24 June 2020. https:\/\/www.who.int\/emergencies\/diseases\/novel-coronavirus-2019\/situation-reports."},{"key":"974_CR65","doi-asserted-by":"publisher","first-page":"1239","DOI":"10.1001\/jama.2020.2648","volume":"323","author":"Z Wu","year":"2020","unstructured":"Wu Z, McGoogan JM. Characteristics of and important lessons from the coronavirus disease 2019 (COVID-19) outbreak in China: summary of a report of 72 314 cases from the Chinese Center for Disease Control and Prevention. JAMA. 2020;323:1239\u201342.","journal-title":"JAMA"},{"key":"974_CR66","doi-asserted-by":"publisher","first-page":"727","DOI":"10.1056\/NEJMoa2001017","volume":"382","author":"N Zhu","year":"2020","unstructured":"Zhu N, Zhang D, Wang W, et al. A novel coronavirus from patients with pneumonia in China, 2019. N Engl J Med. 2020;382:727\u201333.","journal-title":"N Engl J Med"},{"key":"974_CR67","doi-asserted-by":"publisher","first-page":"497","DOI":"10.1016\/S0140-6736(20)30183-5","volume":"395","author":"C Huang","year":"2020","unstructured":"Huang C, Wang Y, Li X, et al. Clinical features of patients infected with 2019 novel coronavirus in Wuhan, China. Lancet. 2020;395:497\u2013506.","journal-title":"Lancet"},{"key":"974_CR68","doi-asserted-by":"publisher","first-page":"1708","DOI":"10.1056\/NEJMoa2002032","volume":"382","author":"W Guan","year":"2020","unstructured":"Guan W, et al. Clinical characteristics of coronavirus disease 2019 in China. N Engl J Med. 2020;382:1708\u201320.","journal-title":"N Engl J Med"},{"key":"974_CR69","doi-asserted-by":"publisher","first-page":"882","DOI":"10.1001\/jamapediatrics.2020.1467","volume":"174","author":"R Castagnoli","year":"2020","unstructured":"Castagnoli R, Votto M, Licari A, et al. Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) infection in children and adolescents: a systematic review. JAMA Pediatr. 2020;174:882\u20139.","journal-title":"JAMA Pediatr"},{"issue":"18","key":"974_CR70","doi-asserted-by":"publisher","first-page":"2000600","DOI":"10.2807\/1560-7917.ES.2020.25.18.2000600","volume":"25","author":"S Garazzino","year":"2020","unstructured":"Garazzino S, Montagnani C, Don\u00e0 D, Italian SITIP-SIP Pediatric Infection Study Group, Italian SITIP-SIP SARS-CoV-2 paediatric infection study group*, et al. Multicentre Italian study of SARS-CoV-2 infection in children and adolescents, preliminary data as at 10 April 2020. Euro Surveill. 2020;25(18):2000600.","journal-title":"Euro Surveill"},{"key":"974_CR71","doi-asserted-by":"publisher","first-page":"653","DOI":"10.1016\/S2352-4642(20)30177-2","volume":"4","author":"F G\u00f6tzinger","year":"2020","unstructured":"G\u00f6tzinger F, Santiago-Garc\u00eda B, Noguera-Juli\u00e1n A, et al. COVID-19 in children and adolescents in Europe: a multinational, multicentre cohort study. Lancet Child Adolesc Health. 2020;4:653\u201361.","journal-title":"Lancet Child Adolesc Health"},{"key":"974_CR72","doi-asserted-by":"publisher","first-page":"187","DOI":"10.1056\/NEJMc2007617","volume":"383","author":"N Parri","year":"2020","unstructured":"Parri N, Lenge M, Buonsenso D, Coronavirus infection in pediatric emergency departments (CONFIDENCE) research group. Children with Covid-19 in pediatric emergency departments in Italy. N Engl J Med. 2020;383:187\u201390.","journal-title":"N Engl J Med"},{"issue":"6","key":"974_CR73","doi-asserted-by":"publisher","first-page":"1088","DOI":"10.1111\/apa.15270","volume":"109","author":"JF Ludvigsson","year":"2020","unstructured":"Ludvigsson JF. Systematic review of COVID-19 in children shows milder cases and a better prognosis than adults. Acta Paediatr. 2020;109(6):1088\u201395.","journal-title":"Acta Paediatr"},{"key":"974_CR74","doi-asserted-by":"publisher","first-page":"371","DOI":"10.1016\/j.jmii.2020.02.011","volume":"53","author":"PI Lee","year":"2020","unstructured":"Lee PI, Hu YL, Chen PY, Huang YC, Hsueh PR. Are children less susceptible to COVID-19? J Microbiol Immunol Infect. 2020;53:371\u20132.","journal-title":"J Microbiol Immunol Infect"},{"key":"974_CR75","doi-asserted-by":"publisher","first-page":"19","DOI":"10.1186\/s12575-020-00128-2","volume":"22","author":"H Esakandari","year":"2020","unstructured":"Esakandari H, Nabi-Afjadi M, Fakkari-Afjadi J, Farahmandian N, Miresmaeili SM, Bahreini E. A comprehensive review of COVID-19 characteristics. Biol Proced Online. 2020;22:19.","journal-title":"Biol Proced Online"},{"issue":"1","key":"974_CR76","doi-asserted-by":"publisher","first-page":"11","DOI":"10.1186\/s12575-020-00124-6","volume":"22","author":"R Zolfaghari Emameh","year":"2020","unstructured":"Zolfaghari Emameh R, Falak R, Bahreini E. Application of system biology to explore the Association of Neprilysin, angiotensin-converting enzyme 2 (ACE2), and carbonic anhydrase (CA) in pathogenesis of SARS-CoV-2. Biological Procedures Online. 2020;22(1):11.","journal-title":"Biological Procedures Online"},{"issue":"6","key":"974_CR77","first-page":"607","volume":"80","author":"Q Ye","year":"2020","unstructured":"Ye Q, Wang B, Mao J. The pathogenesis and treatment of the \u2018cytokine Storm\u2019 in COVID-19. J Inf Secur. 2020;80(6):607\u201313.","journal-title":"J Inf Secur"},{"issue":"38","key":"974_CR78","doi-asserted-by":"publisher","first-page":"e343","DOI":"10.3346\/jkms.2020.35.e343","volume":"35","author":"KM Sohn","year":"2020","unstructured":"Sohn KM, Lee SG, Kim HJ, et al. COVID-19 patients Upregulate toll-like receptor 4-mediated inflammatory signaling that mimics bacterial Sepsis. J Korean Med Sci. 2020;35(38):e343.","journal-title":"J Korean Med Sci"},{"key":"974_CR79","doi-asserted-by":"publisher","first-page":"4123","DOI":"10.2174\/138161206778743466","volume":"12","author":"K Hoebe","year":"2006","unstructured":"Hoebe K, Jiang Z, Georgel P, Tabeta K, Janssen E, Du X, et al. TLR signaling pathways: opportunities for activation and blockade in pursuit of therapy. Curr Pharm Des. 2006;12:4123\u201334.","journal-title":"Curr Pharm Des"},{"key":"974_CR80","doi-asserted-by":"publisher","first-page":"1771","DOI":"10.1016\/S0140-6736(20)31103-X","volume":"395","author":"L Verdoni","year":"2020","unstructured":"Verdoni L, Mazza A, Gervasoni A, et al. An outbreak of severe Kawasaki-like disease at the Italian epicentre of the SARS-CoV-2 epidemic: an observational cohort study. Lancet. 2020;395:1771\u20138.","journal-title":"Lancet."},{"issue":"2","key":"974_CR81","doi-asserted-by":"publisher","first-page":"e20201711","DOI":"10.1542\/peds.2020-1711","volume":"146","author":"F Licciardi","year":"2020","unstructured":"Licciardi F, Pruccoli G, Denina M, et al. SARS-CoV- 2-induced Kawasaki-like hyperinflammatory syndrome: a novel COVID phenotype in children. Pediatrics. 2020;146(2):e20201711.","journal-title":"Pediatrics."},{"key":"974_CR82","doi-asserted-by":"publisher","first-page":"101232","DOI":"10.1016\/j.ppedcard.2020.101232","volume":"57","author":"TR Hennon","year":"2020","unstructured":"Hennon TR, Penque MD, Abdul-Aziz R, et al. COVID-19 associated multisystem inflammatory syndrome in children (MIS-C) guidelines: a Western New York approach. Prog Pediatr Cardiol. 2020;57:101232.","journal-title":"Prog Pediatr Cardiol"},{"key":"974_CR83","doi-asserted-by":"publisher","DOI":"10.1016\/S2213-2600(20)30116-8","volume":"8","author":"L Fang","year":"2020","unstructured":"Fang L, Karakiulakis G, Roth M. Are patients with hypertension and diabetes mellitus at increased risk for COVID-19 infection? Lancet Respir Med. 2020;8:e21.","journal-title":"Lancet Respir Med"},{"key":"974_CR84","doi-asserted-by":"publisher","first-page":"97","DOI":"10.1159\/000375362","volume":"131","author":"W Qiao","year":"2015","unstructured":"Qiao W, Wang C, Chen B, et al. Ibuprofen attenuates cardiac fibrosis in streptozotocin-induced diabetic rats. Cardiology. 2015;131:97\u2013106.","journal-title":"Cardiology."},{"key":"974_CR85","unstructured":"https:\/\/ansm.sante.fr\/S-informer\/Points-d-information-Points-d-information\/COVID-19-l-ANSM-prend-des-mesures-pour-favoriser-le-bon-usage-du-paracetamol. Accessed 17 Mar 2020."},{"key":"974_CR86","doi-asserted-by":"publisher","first-page":"m1185","DOI":"10.1136\/bmj.m1185","volume":"368","author":"P Little","year":"2020","unstructured":"Little P. Non-steroidal anti-inflammatory drugs and covid-19. BMJ. 2020;368:m1185.","journal-title":"BMJ."},{"key":"974_CR87","doi-asserted-by":"crossref","unstructured":"Day M. Covid-19: ibuprofen should not be used for managing symptoms, say doctors and scientists. BMJ. 2020;368:m1086.","DOI":"10.1136\/bmj.m1086"},{"key":"974_CR88","doi-asserted-by":"publisher","first-page":"m1168","DOI":"10.1136\/bmj.m1168","volume":"368","author":"M Day","year":"2020","unstructured":"Day M. Covid-19: European drugs agency to review safety of ibuprofen. BMJ. 2020;368:m1168.","journal-title":"BMJ."},{"key":"974_CR89","unstructured":"https:\/\/www.ansm.sante.fr\/S-informer\/Points-d-information-Points-d-information\/Usage-des-medicaments-en-ville-durant-l-epidemie-de-Covid-19-point-de-situation-apres-cinq-semaines-de-confinement-Point-d-information. Accessed 4 May 2020."},{"key":"974_CR90","volume-title":"Ibuprofen use and Coronavirus (COVID-19)","author":"Medicines and Healthcare products Regulatory Agency","year":"2020","unstructured":"Medicines and Healthcare products Regulatory Agency. Ibuprofen use and Coronavirus (COVID-19). 2020. Available: https:\/\/www.gov.uk\/government\/news\/ibuprofen-use-and-covid19coronavirus [Accessed 24 Mar 2020]."},{"key":"974_CR91","volume-title":"EMA gives advice on the use of non-steroidal anti-inflammatories for COVID-19","author":"European Medicines Agency","year":"2020","unstructured":"European Medicines Agency. EMA gives advice on the use of non-steroidal anti-inflammatories for COVID-19. 2020. https:\/\/www.ema.europa.eu\/en\/news\/ema-gives-advice-use-non-steroidal-anti-inflammatories-covid-19."},{"key":"974_CR92","unstructured":"https:\/\/www.sciencealert.com\/whorecommends-to-avoid-takingibuprofen-for-covid-19-symptoms. Accessed 18 Mar 2020."},{"key":"974_CR93","doi-asserted-by":"publisher","first-page":"1645","DOI":"10.1111\/jpc.15159","volume":"56","author":"J Vosu","year":"2020","unstructured":"Vosu J, Britton P, Howard-Jones A, et al. Is the risk of ibuprofen or other non-steroidal anti-inflammatory drugs increased in COVID-19? J Paediatr Child Health. 2020;56:1645\u20136.","journal-title":"J Paediatr Child Health"},{"key":"974_CR94","doi-asserted-by":"publisher","first-page":"611","DOI":"10.1007\/s40264-020-00953-0","volume":"43","author":"N Moore","year":"2020","unstructured":"Moore N, Carleton B, Blin P, Bosco-Levy P, Droz C. Does ibuprofen worsen COVID-19? Drug Saf. 2020;43:611\u20134.","journal-title":"Drug Saf"},{"key":"974_CR95","doi-asserted-by":"publisher","first-page":"e400","DOI":"10.1097\/MJT.0000000000001196","volume":"27","author":"G Kutti Sridharan","year":"2020","unstructured":"Kutti Sridharan G, Kotagiri R, Chandiramani VH, et al. COVID-19 and avoiding ibuprofen. How good is the evidence? Am J Ther. 2020;27:e400\u20132.","journal-title":"Am J Ther"},{"key":"974_CR96","doi-asserted-by":"publisher","first-page":"55","DOI":"10.1016\/j.chest.2020.03.040","volume":"158","author":"M Sodhi","year":"2020","unstructured":"Sodhi M, Etminan M. Safety of ibuprofen in patients with COVID-19: causal or confounded? Chest. 2020;158:55\u20136.","journal-title":"Chest."},{"key":"974_CR97","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1007\/s40121-020-00363-w","volume":"2","author":"LC Abu Esba","year":"2020","unstructured":"Abu Esba LC, Alqahtani RA, Thomas A, Shamas N, Alswaidan L, Mardawi G. Ibuprofen and NSAID use in COVID-19 infected patients is not associated with worse outcomes: a prospective cohort study. Infect Dis Ther. 2020;2:1\u201316. https:\/\/doi.org\/10.1007\/s40121-020-00363-w Epub ahead of print.","journal-title":"Infect Dis Ther"},{"key":"974_CR98","doi-asserted-by":"publisher","unstructured":"Kragholm K, Gerds TA, Fosb\u00f8l E, et al. Association Between Prescribed Ibuprofen and Severe COVID-19 Infection: A Nationwide Register-Based Cohort Study. Clin Transl Sci. 2020. https:\/\/doi.org\/10.1111\/cts.12904 Epub ahead of print.","DOI":"10.1111\/cts.12904"},{"key":"974_CR99","doi-asserted-by":"publisher","first-page":"1259.e5","DOI":"10.1016\/j.cmi.2020.06.003","volume":"26","author":"E Rinott","year":"2020","unstructured":"Rinott E, Kozer E, Shapira Y, Bar-Haim A, Youngster I. Ibuprofen use and clinical outcomes in COVID-19 patients. Clin Microbiol Infect. 2020;26:1259.e5\u20137.","journal-title":"Clin Microbiol Infect"}],"container-title":["Italian Journal of Pediatrics"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s13052-021-00974-0.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1186\/s13052-021-00974-0\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s13052-021-00974-0.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,1,28]],"date-time":"2023-01-28T20:04:02Z","timestamp":1674936242000},"score":1,"resource":{"primary":{"URL":"https:\/\/ijponline.biomedcentral.com\/articles\/10.1186\/s13052-021-00974-0"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2021,1,29]]},"references-count":99,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2021,12]]}},"alternative-id":["974"],"URL":"https:\/\/doi.org\/10.1186\/s13052-021-00974-0","relation":{},"ISSN":["1824-7288"],"issn-type":[{"value":"1824-7288","type":"electronic"}],"subject":[],"published":{"date-parts":[[2021,1,29]]},"assertion":[{"value":"4 August 2020","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"21 January 2021","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"29 January 2021","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"Not applicable.","order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval and consent to participate"}},{"value":"Not applicable.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent for publication"}},{"value":"The authors declare no conflict of interest to disclose regards to this paper; AS is clinical investigator for Janssen Biologics B.V. and PAREXEL International Srl, served as consultant for Aboca, for D.M.G. Italy and Nestl\u00e9, and as safety monitoring board member for Sucampo AG and as speaker for Aboca, Angelini, D.M.G. Italy, Valeas.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"20"}}